Journal: International Journal of Chronic Obstructive Pulmonary Disease
Article Title: Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
doi: 10.2147/COPD.S185485
Figure Lengend Snippet: Baseline demographics and clinical characteristics
Article Snippet: Patients who consented and fulfilled all inclusion/exclusion criteria were instructed to interrupt their ongoing maintenance treatment regimen for 24 hours for patients on od tiotropium (18 µg via Handihaler device; Boehringer Ingelheim, Ingelheim, Germany), or 12 hours for patients on bid SFC FDC (any dose, any device; GlaxoSmithKline plc, London, UK), to allow baseline assessment.
Techniques: